Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

D. E. Furst, E. C. Keystone, B. Kirkham, R. Fleischmann, P. Mease, F. C. Breedveld, J. S. Smolen, J. R. Kalden, G. R. Burmester, J. Braun, P. Emery, Kevin Winthrop, B. Bresnihan, F. De Benedetti, T. Dörner, A. Gibofsky, M. H. Schiff, J. Sieper, N. Singer, P. L C M Van RielM. E. Weinblatt, M. H. Weisman

Research output: Contribution to journalArticle

101 Scopus citations

Abstract

Rituximab is effective in patients with an inadequate response to MTX for whom conventional DMARDS have failed or have one or more TNFα blocking agents. The safety of rituximab is still being defined. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents.

Original languageEnglish (US)
JournalAnnals of the Rheumatic Diseases
Volume67
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Dec 2008

    Fingerprint

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Furst, D. E., Keystone, E. C., Kirkham, B., Fleischmann, R., Mease, P., Breedveld, F. C., ... Weisman, M. H. (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Annals of the Rheumatic Diseases, 67(SUPPL. 3). https://doi.org/10.1136/ard.2008.100834